JP2011508727A5 - - Google Patents

Info

Publication number

JP2011508727A5

JP2011508727A5 JP2010538227A JP2010538227A JP2011508727A5 JP 2011508727 A5 JP2011508727 A5 JP 2011508727A5 JP 2010538227 A JP2010538227 A JP 2010538227A JP 2010538227 A JP2010538227 A JP 2010538227A JP 2011508727 A5 JP2011508727 A5 JP 2011508727A5

Authority

JP

Japan

Prior art keywords

seq

salt

peptide

pharmaceutical composition

hydrochloride

Prior art date

2008-12-15

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003839 salts Chemical class 0.000 claims description 21
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
• 229940009098 aspartate Drugs 0.000 claims description 5
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
• 206010064147 Gastrointestinal inflammation Diseases 0.000 claims description 2
• 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 claims description 2
• 102100028647 Mu-type opioid receptor Human genes 0.000 claims description 2
• 206010013663 drug dependence Diseases 0.000 claims description 2
• 230000000694 effects Effects 0.000 claims description 2
• 230000004054 inflammatory process Effects 0.000 claims description 2
• 208000011117 substance-related disease Diseases 0.000 claims description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
• 102000004196 processed proteins & peptides Human genes 0.000 claims 2
• 230000000202 analgesic effect Effects 0.000 description 1
• 239000000203 mixture Substances 0.000 description 1